404 related articles for article (PubMed ID: 12604403)
1. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
van der Pol MA; Broxterman HJ; Pater JM; Feller N; van der Maas M; Weijers GW; Scheffer GL; Allen JD; Scheper RJ; van Loevezijn A; Ossenkoppele GJ; Schuurhuis GJ
Haematologica; 2003 Feb; 88(2):134-47. PubMed ID: 12604403
[TBL] [Abstract][Full Text] [Related]
2. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia.
van der Pol MA; Pater JM; Feller N; Westra AH; van Stijn A; Ossenkoppele GJ; Broxterman HJ; Schuurhuis GJ
Leukemia; 2001 Oct; 15(10):1554-63. PubMed ID: 11587213
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract][Full Text] [Related]
7. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia.
Benderra Z; Faussat AM; Sayada L; Perrot JY; Tang R; Chaoui D; Morjani H; Marzac C; Marie JP; Legrand O
Clin Cancer Res; 2005 Nov; 11(21):7764-72. PubMed ID: 16278398
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
[TBL] [Abstract][Full Text] [Related]
9. Novel mechanisms of drug resistance in leukemia.
Ross DD
Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
[TBL] [Abstract][Full Text] [Related]
11. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
13. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
Kovalev AA; Tsvetaeva DA; Grudinskaja TV
Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
[TBL] [Abstract][Full Text] [Related]
14. ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.
Sakata S; Fujiwara M; Ohtsuka K; Kamma H; Nagane M; Sakamoto A; Fujioka Y
Oncol Rep; 2011 Feb; 25(2):333-9. PubMed ID: 21165575
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
Damiani D; Tiribelli M; Michelutti A; Geromin A; Cavallin M; Fabbro D; Pianta A; Malagola M; Damante G; Russo D; Fanin R
Leuk Res; 2010 Jul; 34(7):942-5. PubMed ID: 20122734
[TBL] [Abstract][Full Text] [Related]
16. Transport proteins in drug resistance: detection and prognostic significance in acute myeloid leukemia.
Broxterman HJ; Schuurhuis GJ
J Intern Med Suppl; 1997; 740():147-51. PubMed ID: 9350197
[TBL] [Abstract][Full Text] [Related]
17. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.
Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
Blood; 1998 Jun; 91(12):4480-8. PubMed ID: 9616142
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
Leslie EM; Deeley RG; Cole SP
Toxicol Appl Pharmacol; 2005 May; 204(3):216-37. PubMed ID: 15845415
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]